Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (781-790 of 1,482) with videos related to

Pageof 149
Sort By:
American Journal of Hematology|October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapyKoji Sasaki, Tapan Kadia, Kebede Begna, et al.
American Journal of Hematology|August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experiencePrajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Human Molecular Genetics|April 3, 2022
Genetic risk factors and COVID-19 severity in Brazil: results from BRACOVID studyAlexandre C Pereira, Taniela M Bes, Mariliza Velho, et al.
Antimicrobial Agents and Chemotherapy|July 14, 2001
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitisC B Kurtz, E P Cannon, A Brezzani, et al.
The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.
Blood|July 3, 2025
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemiaBing Z Carter, Po Yee Mak, Edward Ayoub, et al.
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
Leukemia|September 15, 2015
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndromeN Daver, H Kantarjian, F Ravandi, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Pageof 149

Showing results (781-790 of 1,482) with videos related to

Sort By:
Pageof 149
American Journal of Hematology|October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapyKoji Sasaki, Tapan Kadia, Kebede Begna, et al.
American Journal of Hematology|August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experiencePrajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Human Molecular Genetics|April 3, 2022
Genetic risk factors and COVID-19 severity in Brazil: results from BRACOVID studyAlexandre C Pereira, Taniela M Bes, Mariliza Velho, et al.
Antimicrobial Agents and Chemotherapy|July 14, 2001
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitisC B Kurtz, E P Cannon, A Brezzani, et al.
The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.
Blood|July 3, 2025
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemiaBing Z Carter, Po Yee Mak, Edward Ayoub, et al.
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
Leukemia|September 15, 2015
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndromeN Daver, H Kantarjian, F Ravandi, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Pageof 149